|
The history of cannabis products and their use has been long, colorful and varied. "To the agriculturist, cannabis is a fiber crop; to the physician, it is an enigma; to the user, a euphoriant; to the police, a menace; to the trafficker, a source of profitable danger; to the convict or parolee and his family, a source of sorrow" (Mikuriya, 1969: 34). The fact is that cannabis has been held simultaneously in high and low esteem at various times throughout recorded history, particularly in our own times.
The volume of information available on the medical application of cannabis is considerable. Occasionally certain references have been condensed or deleted, but this should not detract from the completeness of the report. This historical survey of the medical uses of marihuana is introduced by abroad overview of its use, including brief notes on current and projected research, and then considers specific historical settings and circumstances in ancient China, moving on to Egypt, India, Greece, Africa, and the Western World. Cannabis sativa has been used therapeutically from the earliest records, nearly 5,000 years ago, to the present day (Mikuriya, 1969: 34) and its products have been widely noted for their effects, both physiological and psychological, throughout the world. Although the Chinese and Indian cultures knew about the properties of this drug from very early times, this information did not become general in the Near and Middle East until after the fifth century A.D., when travelers, traders and adventurers began to carry knowledge of the drug westward to Persia and Arabia. Historians claim that cannabis was first employed in these countries as an antiseptic and analgesic. Other medical uses were later developed and spread throughout the Middle East, Africa, and Eastern Europe. Several years after the return of Napoleon's army from Egypt, cannabis became widely accepted by Western medical practitioners. Previously, it had had limited use for such purposes as the treatment of burns. The scientific members of Napoleon's forces were interested in the drug's pain relieving and sedative effects. It was used during, and to a greater extent, following his rule in France, especially after 1840 when the work of such physicians as O'Shaughnessy, Aubert-Roche, and Moreau de Tours drew wide attention to this drug. With the rise of the literary movement of the 1840-1860 period in France (Gautier, Baudelaire, Dumas, etc.), cannabis became somewhat popular as an intoxicant of the intellectual classes. In the United States, medical interest in cannabis use was evidenced in 1860 by the convening of a Committee on Cannabis Indica of the Ohio State Medical Society, which reported on its therapeutic applications (McMeens, 1860: 1). Between the period 1840-1890, Walton states that more than 100 articles were published recommending cannabis for one disorder or another. Concern about cannabis as an intoxicant led the government of India to establish the India Hemp Commission of 1893-94 to examine the entire question of cannabis use in India. Paralleling the question over cannabis use in the latter half of the 19th century was the growing medical use of other medications superior to cannabis in their effects and more easily controlled as to dose. Consequently, medical use of cannabis declined and cannabis began to lose support of the medical profession. During the years between 1856-1937, cannabis lost its image as a medicine and was left with a disreputable image as an intoxicant. Strong public reaction coupled with a campaign in the public press led to a federal anti-marihuana law in 1937. (The drug was illegal in many states before 1937.) The issue of medical use remained active, however, and Dr. William C. Woodward, Legislative Counsel to the AMA, an opponent of cannabis use and the only physician to be a witness at the Taxation of Marihuana hearings, stated: "There are exceptions in treatment in which cannabis cannot apparently be successfully subsituted for. The work of Pascal seems to show that Indian Hemp has remarkable properties in revealing the subconscious; hence, it can be used for psychological, psychoanalytic and psychotherapeutic research". (Hearings, House of Representatives, 1937: 91). Information obtained www.skunked.co.uk
China
The oldest known therapeutic description of cannabis was by the Emperor Shen-Nung in the 28th century B.C. in China, where the plant had long been grown for fiber. He prescribed cannabis for beri-beri, constipation, "female weakness," gout, malaria, rheumatism and absentmindedness (Bloomquist, 1968: 19). Egypt In Egypt, in the 20th century B.C., cannabis was used to treat sore eyes. Additional medical usage was not reported until much later. India Prior to the 10th century B.C., bhang, a cannabis preparation, was used as an anesthetic and antiphlegmatic in India. In the second century A.D., a Chinese physician, Hoa-Tho, prescribed it as an analgesic in surgical procedures (Mikuriya, 1969: 34). From the 10th century B.C. up to 1945 (and even to the present time), cannabis has been used in India to treat a wide variety of human maladies. The drug is highly regarded by some medical practitioners in that country. The religious use of cannabis in India is thought to have preceded its medical use (Blum and Associates, II, 1969: 73; Snyder, 1970: 125). The religious use of cannabis is to help "the user to free his mind from worldly distractions and to concentrate on the Supreme Being" (Barber, 1970: 80). Cannabis is used in Hindu and Sikh temples and at Mohammedan shrines. Besides using the drug as an aid to meditation, it is also used to overcome hunger and thirst by the religious mendicants. In Nepal, it is distributed on certain feast days at the temples of all Shiva followers (Blum & Associates, 1969, 11: 63). The Hindus spoke of the drug as the "heavenly guide," "the soother of grief." Considered holy, it was described as a sacred grass during the Vedic period (Fort, 1969: 15). A reference to cannabis in Hindu scriptures is the following: to the Hindu the hemp plant is holy. A guardian lives in bhang ... Bhang is the joy giver, the sky filer, the heavenly guide, the poor man's heaven, the soother of grief ... No god or man is as good as the religious drinker of Mang. The students of the scriptures of Benares are given bhang before they sit to study. At Benares, Ujjain and other holy places, yogis take deep draughts of Mang that they may center their thoughts on the Eternal . . . By the help of Mang ascetics pass days without food or drink. The supporting power of Mang has brought many a Hindu family safe through the miseries of famine (Snyder, 1970: 125). Greece In ancient Greece, cannabis was used as a remedy for earache, edema, and inflammation (Robinson, 1946: 382-383). Africa Cannabis was used in Africa to restore appetite and to relieve pain of hemorrhoids, its antiseptic uses were also known to certain African native tribes (O'Shaughnessy, 1842: 431). Various other uses, in a number of countries, included the treatment of tetanus, hydrophobia, delirium tremens, infantile convulsions, neuralgia and other nervous disorders, cholera, menorrhagia, rheumatism, hay fever, asthma, skin diseases, and protracted labor during childbirth. Information obtained www.skunked.co.uk
Cannabis was a part of the American pharmacopoeia until 1942 and is currently available by prescription in the Netherlands, Canada, Spain, and Italy in its whole plant form.
In 1937, the U.S. passed the first federal law against cannabis, despite the objections of the American Medical Association (AMA). Dr. William C. Woodward, testifying on behalf of the AMA, told Congress that, "The American Medical Association knows of no evidence that marijuana is a dangerous drug" and warned that a prohibition "loses sight of the fact that future investigation may show that there are substantial medical uses for Cannabis." Ironically, the U.S. federal government currently grows and provides cannabis for a small number of patients. In 1976 the federal government created the Investigational New Drug (IND) compassionate access research program to allow patients to receive up to nine pounds of cannabis from the government each year. Today, five surviving patients still receive medical cannabis from the federal government, paid for by federal tax dollars. In 1988, the DEA's Chief Administrative Law Judge, Francis L. Young, ruled after extensive hearings that, "Marijuana, in its natural form, is one of the safest therapeutically active substances known... It would be unreasonable, arbitrary and capricious for the DEA to continue to stand between those sufferers and the benefits of this substance..." Yet the DEA refused to implement this ruling based on a procedural technicality and resists rescheduling to this day. In 1989, the FDA was flooded with new applications from people with HIV/AIDS. In June 1991, the Public Health Service announced that the program would be suspended because it undermined federal prohibition. Despite this successful medical program and centuries of documented safe use, cannabis is still classified in America as a Schedule I substance “indicating a high potential for abuse and no accepted medical value. Healthcare advocates have tried to resolve this contradiction through legal and administrative channels to no avail. In 1996, patients and advocates turned to the state level for access, passing voter initiatives in California and Arizona that allowed for legal use of cannabis with a doctor's recommendation. These victories were followed by the passage of similar initiatives in Alaska, Colorado, Maine, Montana, Nevada, Oregon, Washington, and Washington D.C. The legislatures of Hawaii, Maryland, New Mexico Rhode Island, and Vermont have also acted on behalf of their citizens, and every legislative session sees more bills introduced at the state level across the country. In 1997, The Office of National Drug Control Policy commissioned the Institute of Medicine (IOM) to conduct a comprehensive study of the medical efficacy of cannabis therapeutics. The IOM concluded that cannabis is a safe and effective medicine, patients should have access, and the government should expand avenues for research and drug development. The federal government has completely ignored its findings and refused to act on its recommendations. Despite the federal barriers to research, hundreds of peer-reviewed studies have been published worldwide since the IOM report. While there is still much to learn, the medical potential is indisputable for a variety of symptoms and conditions. In 1997, the federal government began a campaign to arrest and prosecute medical cannabis patients and their providers. These raids resulted in two Supreme Court Cases, OCBC and Gonzales v. Raich. In each of these cases the Justices found that the federal law and state law can exist in conflict and that the federal government could continue their campaign against medical cannabis patients if they so choose. However, the Justices questioned "the wisdom' of going after patients and their providers and called on Congress to change the current laws to allow for medical use. Since the U.S. Supreme Court decision in Gonzales v. Raich, on June 6, 2005, the federal government has intensified its war against patients across the state of California. These raids have resulted in more than two-dozen patients and providers being needlessly prosecuted by the federal government. Unfortunately, these defendants will not be permitted to mention during trial that their use of cannabis was for legitimate purposes and in accordance with state law. These raids alone are estimated to have cost taxpayers over $10,000,000. Patients who could and do benefit from cannabis therapeutics face a variety of challenges at both the federal and state levels. Patients have been made to needlessly suffer because they have been denied access or, worse, because they have been imprisoned for using a medicine their doctors recommended. Medical cannabis patients and current Executive Director Steph Sherer founded Americans for Safe Access (ASA) in 2002 in response to federal raids on patients in California. Ever since then, ASA has been instrumental in shaping the political and legal landscape of medical cannabis. Our successful lobbying, media, and legal campaigns led to positive court precedents, new sentencing standards, more compassionate legislative and administrative polices and procedures, as well as new legislation. Information obtained thru Americans for Safe Access. www.safeaccessnow.org |
||
